Morgan Stanley reaffirmed their equal weight rating on shares of Hikma Pharmaceuticals Plc (OTC:HKMPF) in a research note issued to investors on Wednesday, MarketBeat reports.

A number of other brokerages also recently issued reports on HKMPF. Numis Securities Ltd reissued an add rating on shares of Hikma Pharmaceuticals Plc in a research report on Friday, May 19th. Jefferies Group LLC downgraded Hikma Pharmaceuticals Plc from a buy rating to an underperform rating in a research report on Wednesday, May 17th. Finally, ValuEngine raised Hikma Pharmaceuticals Plc from a hold rating to a buy rating in a research report on Thursday, July 27th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the stock. The company presently has a consensus rating of Hold and an average price target of $27.00.

Hikma Pharmaceuticals Plc (OTC HKMPF) remained flat at $18.60 during trading on Wednesday. The company has a 50 day moving average of $20.32 and a 200-day moving average of $23.55. The company has a market cap of $4.48 billion and a PE ratio of 28.10. Hikma Pharmaceuticals Plc has a 52 week low of $18.15 and a 52 week high of $29.75.

TRADEMARK VIOLATION WARNING: “Hikma Pharmaceuticals Plc (HKMPF) Stock Rating Reaffirmed by Morgan Stanley” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at

Receive News & Stock Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related stocks with our FREE daily email newsletter.